On february 27, 2019 Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat life-threatening conditions, reported it will present three posters on TP-2846, the Company’s newly revealed pipeline candidate for acute myeloid leukemia (AML) (Press release, Tetraphase Pharmaceuticals, FEB 27, 2019, View Source [SID1234533750]). The posters will be presented at the 2019 American Association for Clinical Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place March 29 – April 3 at the Georgia World Congress Center in Atlanta. The poster presentations will include in vitro and in vivo data supporting TP-2846’s potential as a novel tetracycline antileukemia agent.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Decades of research have shown that tetracyclines hold potential as anticancer agents, but to date, optimizing a tetracycline for oncology has proven elusive," said Guy Macdonald, President and Chief Executive Officer. "Leveraging our proprietary and productive discovery platform, we identified TP-2846, a structurally diverse tetracycline and potential new antileukemia agent with potent in vitro and in vivo activity. We look forward to further discussing the potential of TP-2846 at AACR (Free AACR Whitepaper) and building on this encouraging preclinical dataset."
"TP-2846 represents a new mechanism of action with potential application for AML patients regardless of mutation status," said Jacques Dumas, Ph.D., Chief Scientific Officer. "By using our fully synthetic technology for building tetracyclines, we have been able to optimize TP-2846 for AML, warranting its further study in this patient population."
The details for the data presentations at AACR (Free AACR Whitepaper) are as follows:
Abstract Number: 3857
Title: Discovery and structure-activity relationship studies of TP-2846: a novel tetracycline antileukemia agent
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 2
Session Date and Time: Tuesday, April 2, 2019 from 1:00 PM – 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 12
Abstract Number: 3880
Title: In vivo activities of TP-2846: a novel tetracycline antileukemia agent
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 2
Session Date and Time: Tuesday, April 2, 2019 from 1:00 PM – 5:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 12
Abstract Number: 4802
Title: In vitro characterization of TP-2846: a novel tetracycline antileukemia agent
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 3
Session Date and Time: Wednesday, April 3, 2019 from 8:00 AM – 12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 13